United Therapeutics Corporation Stock price

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
234 USD -0.77% Intraday chart for United Therapeutics Corporation -6.23% +6.40%
Sales 2024 * 2.7B Sales 2025 * 2.82B Capitalization 11.01B
Net income 2024 * 1.2B Net income 2025 * 1.23B EV / Sales 2024 * 2.86 x
Net cash position 2024 * 3.3B Net cash position 2025 * 4.14B EV / Sales 2025 * 2.44 x
P/E ratio 2024 *
9.86 x
P/E ratio 2025 *
9.56 x
Employees 1,168
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.77%
1 week-3.74%
Current month+3.69%
1 month+8.96%
3 months-5.06%
6 months+6.23%
Current year+6.40%
More quotes
1 week
229.55
Extreme 229.545
250.36
1 month
213.75
Extreme 213.75
250.36
Current year
208.62
Extreme 208.6249
250.36
1 year
204.44
Extreme 204.44
261.54
3 years
158.38
Extreme 158.38
283.09
5 years
74.31
Extreme 74.31
283.09
10 years
74.31
Extreme 74.31
283.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 96-06-25
President 52 11-03-31
Director of Finance/CFO 56 12-12-31
Members of the board TitleAgeSince
Director/Board Member 76 01-12-31
Chief Executive Officer 69 96-06-25
Director/Board Member 81 09-12-31
More insiders
Date Price Change Volume
24-03-18 234 -0.77% 447,746
24-03-15 235.8 -0.98% 898,652
24-03-14 238.1 -1.31% 360,288
24-03-13 241.3 -2.27% 489,153
24-03-12 246.9 -1.06% 374,481

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
234 USD
Average target price
287 USD
Spread / Average Target
+22.67%
Consensus
  1. Stock
  2. Equities
  3. Stock United Therapeutics Corporation - Nasdaq